Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Yahoo FinanceApr 26 12:35 ET
Express News | Ocugen Says It Will Present On Modifier Gene Therapy Platform At Association For Research In Vision And Ophthalmology 2024 Annual Meeting
BenzingaApr 26 06:36 ET
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna
BenzingaApr 22 08:32 ET
Express News | Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $5
Moomoo 24/7Apr 22 07:47 ET
Ocugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 267.65% Chardan Capital $4 → $5 Maintains Buy 04/03/2024 414.71% HC Wainwright & Co. → $7 Reite
BenzingaApr 22 07:44 ET
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Ocugen (OCGN) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration.
MT NewswiresApr 19 08:19 ET
Express News | Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
Moomoo 24/7Apr 19 07:13 ET
Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 19 00:00 ET
Ocugen Stock Jumps After $175M Securities Filing
Seeking AlphaApr 18 06:21 ET
Express News | Ocugen Inc Files for Mixed Shelf of up to $175 Mln - SEC Filing
Moomoo 24/7Apr 18 06:02 ET
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To...
Stockhouse Apr 14 11:00 ET
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 12 00:00 ET
Ocugen Says EU Backs a U.S. Trial for Gene Therapy
Seeking AlphaApr 10 10:20 ET
Express News | Ocugen Disclosed Positive Scientific Advice From The European Medicines Agency Related To The Approval Pathway For Ocu400—Modifier Gene Therapy For Broad Retinitis Pigmentosa Indication
Moomoo 24/7Apr 10 07:05 ET
Ocugen, Inc. Announces Positive Scientific Advice From the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 10 00:00 ET
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
TipRanksApr 9 08:10 ET
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Yahoo FinanceApr 8 12:13 ET
FDA Clears Ocugen's Phase 3 Trial for Rare Retinal Disease Therapy
InvestingApr 8 11:32 ET
Why Ocugen Shares Are Trading Higher
Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 7.7% to $1.97 during Monday's session after the company announced U.S. FDA clearance of the IND amendment to initiate a Phase 3 clinical trial of
BenzingaApr 8 11:08 ET
Dow futures are rising and there is also an atmosphere of waiting for this week's inflation statistics = US stocks
Dow futures, S&P 500, and NASDAQ 100 are all rising in the US stock index futures market. This year's rising market came to an end last week, and the wait-and-see atmosphere is spreading today.
MinkabuApr 8 09:13 ET
No Data
No Data